Role of Chemokine and Chemokine Receptor in Psoriasis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03302390|
Recruitment Status : Withdrawn (PI failed to submit study for continuing review by IRB)
First Posted : October 5, 2017
Last Update Posted : October 17, 2018
|Condition or disease||Intervention/treatment|
|Psoriasis||Procedure: Shave Biopsy of Psoriasis Lesion|
|Study Type :||Observational|
|Actual Enrollment :||0 participants|
|Official Title:||Role of Chemokine and Chemokine Receptor in Psoriasis|
|Actual Study Start Date :||April 17, 2017|
|Actual Primary Completion Date :||April 13, 2018|
|Actual Study Completion Date :||April 13, 2018|
Biopsy of Skin with Psoriasis
Shave biopsy of psoriasis lesion
Procedure: Shave Biopsy of Psoriasis Lesion
The investigator will take about 0.5x0.5 inch square section of skin from the psoriasis lesion. To numb the skin, the subject will receive a small injection of 0.5% lidocaine HCl 5mg/mL with 1:200,000 mcg/mL epinephrine solution as per standard shave biopsy protocol. The shaving instrument has a blade that will shave off a superficial piece of skin that is less than <3mm in thickness. After 14 days, the subject will return to make sure that the skin biopsy site has healed properly. The piece of skin that is removed will be grafted onto the back of an immunocompromised SCID mouse. An approved IACUC protocol covering this procedure will be in place prior to engraftment.
- Acquisition of psoriatic skin from patient to transfer to immunocompromised mice [ Time Frame: Five years ]The purpose of this human clinical trial is to harvest psoriatic skin for engraftment onto immunocompromised mice. The primary outcome measure is to identify a 0.75 x 0.75 square inch piece of skin with psoriasis on study subjects to be biopsied. specific outcome measure that will be obtained in the patients other than ensuring that their graft sites heal appropriately. Their skin, once placed on immunocompromised mice, will be used to test new therapeutic drugs which might have a beneficial outcome in psoriasis, as measured in this mouse model.
- Observe Appropriate Healing in Subject Biopsy sites [ Time Frame: Five years ]The secondary outcome measure is to observe that study subjects' graft sites heal appropriately.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03302390
|United States, California|
|Sacramento, California, United States, 95817|
|Principal Investigator:||Samuel Hwang, M.D.||University of California, Davis|